Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property Routine +

Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings

Crescita Therapeutics Moves Closer to ClinActiv Takeover at $0.80 Premium

By The Northwire Desk — AI Analysis Apr 22, 2026 · 19:13 CTX · 0.74 CRESCITA THERAPEUTICS INC. J
Executive Summary
  • Crescita Therapeutics has mailed management information circulars for a special shareholder meeting scheduled for May 14, 2026.
  • The meeting is to approve a plan of arrangement for acquisition by ClinActiv Holdings Inc.
  • Transaction terms remain an all-cash purchase at $0.80 per share, with a minimum floor price of $0.75 per share based on net working capital adjustments.
  • Approximately 33% of outstanding shares are committed via voting and support agreements from significant shareholders and management.
  • An interim order regarding the arrangement was issued by the Ontario Superior Court of Justice on April 10, 2026.
  • Expected closing is in the second quarter of 2026, followed by delisting from the TSX and cessation as a reporting issuer.
Material Impact
  • The news represents procedural progress rather than new fundamental value; the acquisition was definitively announced on March 16, 2026.
  • Stock price has already adjusted to reflect the $0.80 offer price, trading at $0.74-$0.75 since mid-March.
  • The confirmation of the shareholder meeting date and court interim order reduces execution risk but does not alter valuation expectations.
  • No new financial terms or strategic shifts are introduced; this is a standard step in the M&A timeline.
  • The market has already priced in the deal, making this announcement incremental rather than transformative.
CTX · Price
Company Overview
  • Crescita Therapeutics operates in skincare and contract manufacturing sectors.
  • Flagship Project: Acquisition by ClinActiv Holdings Inc., which will retain commercial skincare and contract manufacturing business.
  • Senior management retains remaining assets post-closing under a reorganization agreement.
  • Key operational highlights include lease renewal through 2031 and asset acquisition of Laboratoire Provence-Canada Inc. for $775k.
  • Revenue growth driven by manufacturing volumes, with FY2025 revenue up 7.9% to $21.1M.
Read the original news release →

More from CRESCITA THERAPEUTICS INC. J

Jun 03, 2026 · 18:07

Crescita Therapeutics Closes $0.80 All-Cash Acquisition by ClinActiv, Delisting TSX and Cashing Out Shareholders

M&A / Property Jun 01, 2026 · 20:59

Crescita Therapeutics Inc.

M&A / Property May 20, 2026 · 17:07

Crescita Therapeutics Secures Final Court Approval for ClinActiv Acquisition; Shares Trade Near Offer Price

M&A / Property May 14, 2026 · 13:48

Crescita shareholders overwhelmingly back ClinActiv buyout, paving the way for a clean exit at the premium offer.

M&A / Property May 11, 2026 · 07:30

Crescita Shares Trade Near Buyout Price as Q1 EBITDA Turnaround Validates Deal Viability

Earnings Mar 31, 2026 · 07:30

Crescita Locks $0.80 Buyout as Q4 Earnings Validate Manufacturing Pivot

Earnings